Immunologic effects of locoregional therapies for unresectable hepatocellular carcinoma.

ABSTRACT:

Background & aims

The combination of locoregional therapies (LRT) with immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma (HCC) is expected to enhance immune-mediated anti-tumor effects. Although clinical trials are underway, an unmet need exists to understand the immunological effects of LRT and how they evolve. This study aimed to longitudinally assess immune cell subpopulations and checkpoint expression after LRT.

Methods

This prospective, single-center study (DRKS00026994) enrolled 128 consecutive patients with unresectable HCC, who underwent conventional transarterial chemoembolization (cTACE), interstitial high-dose-rate brachytherapy (iBT), or a combination of cTACE and iBT (from July 2020 to September 2021). Peripheral blood samples were col

SUBMITTER: Schmidt R 

PROVIDER: S-EPMC12637058 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature